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PENILAIAN KESAN PERLINDUNGAN HATI OLEH 
TOKOTRIENOL DAN HUBUNGAN HATI BERLEMAK BUKAN-
ALKOHOLIK DENGAN LUKA BAHAN-PUTIH OTAK
ABSTRAK
Penyakit hati berlemak bukan-alkoholik adalah salah satu masalah hati yang paling 
biasa terdapat seluruh dunia. Namun, tiada data mengenai prevalen atau kadar 
berlakunya penyakit ini bagi Malaysia boleh diperolehi daripada kajian sistematik. 
Dalam kajian ini, 180 orang dewasa lelaki dan wanita yang didapati sedikit 
hiperkolesterolemik semasa memasuki kajian ini telah disaring menggunakan 
imbasan ultrasound untuk menentukan kehadiran hati berlemak bukan-alkoholik. 
Kadar didapati tinggi dengan hampir 60% daripada jumlah peserta didiagnosis 
menghidapi penyakit hepatik ini. Penyakit hati berlemak bukan-alkoholik melibatkan 
penyusupan lemak ke dalam hati dan buat masa ini, tiada rawatan farmakologikal 
tersedia ada.
Penyaringan tersebut adalah sebahagian daripada proses perekrutan bagi kajian 
pembutaan-dua kali plasebo-terkawal yang bertujuan untuk menilai aktiviti 
tokotrienol dalam rawatan penyakit hati berlemak bukan-alkoholik. Tokotrienol, 
yang diekstrak daripada minyak kelapa sawit, adalah ahli  kumpulan vitamin E.
Penilaian kesan tokotrienol untuk rawatan penyakit hati berlemak bukan-alkoholik 
telah dijalankan dengan membandingkan ekogenisiti hati pada tahap dasar dengan 
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pada akhir kajian. Hiperekogenisiti hati adalah berkadar terus dengan kandungan 
lemak.
Kajian ini pada mulanya telah merekrut 87 orang dewasa berhiperkolesterolemik 
yang telah dibahagikan secara rawak kepada dua kumpulan rawatan: samada plasebo 
(n=44) atau tokotrienol 400 mg/hari (n=43) selama satu tahun. Terdapat enam puluh 
empat subjek pada akhir kajian ini, 30 dalam kumpulan tokotrienol dan 34 dalam 
kumpulan plasebo.
Keberkesanan rawatan telah ditunjukkan, iaitu subjek yang dirawat dengan 
tokotrienol menunjukkan kadar penyembuhan (p=0.014; OR = 3.250; 95% CI = 
1.117-9.456) dan penambahbaikan (p=0.021; OR=2.857; 95% CI=1.029-7.934) yang 
signifikan.
Aktiviti tokotrienol untuk menghalang penyakit hati berlemak bukan-alkoholik 
daripada bermula telah dinilai seterusnya dalam model haiwan. Satu diet steatogenik 
ad hoc telah  diformulasi dan diberikan kepada mencit.Kajian histologi telah 
menunjukkan bahawa haiwan yang diberikan diet steatogenik telah mendapat 
penyakit hati berlemak bukan-alkoholik, manakala haiwan yang diberikan diet yang 
sama tetapi ditambah dengan tokotrienol tidak mendapat penyakit tersebut.
Hati berlemak bukan-alkoholik merupakan komponen hepatik bagi sindrom 
metabolik dan berkongsi faktor-faktor risiko yang sama dengan komponen serebral 
bagi sindrom tersebut, iaitu luka bahan-putih otak. Luka bahan-putih otak nampak 
sebagai hiperintensiti pada imbasan resonan magnetik dan mewakili bahagian infark 
subklinikal. 
Imbasan otak bagi 172 subjek yang telah disaring bagi kehadiran penyakit hati 
berlemak bukan-alkoholik telah diambil. Hubungan antara luka bahan-putih otak dan 
xv
penyakit hati berlemak bukan-alkoholik yang dibuktikan dengan ultrasound telah 
ditunjukkan bagi kali pertamanya di kalangan orang dewasa berusia lebih 50 tahun 
(Chi-square=6.778; p<0.01).
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EVALUATION OF THE HEPATOPROTECTIVE EFFECTS OF 
TOCOTRIENOLS AND THE RELATIONSHIP BETWEEN NON-
ALCOHOLIC FATTY LIVER AND BRAIN WHITE-MATTER 
LESIONS
ABSTRACT
Non-alcoholic fatty liver disease is one of the most common liver disorders 
worldwide. However, no data from systematic studies are available for Malaysia on 
prevalence or rate of this disease.
In the present study 180 walk-in mildly hypercholesterolemic adults of both genders 
were screened using ultrasound imaging to determine the presence of non-alcoholic 
fatty liver. The rate of this hepatic disease was found to be high, since it was 
diagnosed in almost 60% of the participants. Non-alcoholic fatty  liver disease 
consists of fat  infiltration in the liver, at present no pharmacological treatment is 
available.
The screening was part of the recruitment process for a double-blind placebo-
controlled study  aimed at evaluating the activity  of tocotrienols for the treatment  of 
non-alcoholic fatty liver disease. Tocotrienols, that are extracted from palm oil, are 
members of the vitamin E family.
Evaluation of the effects of tocotrienols for treatment of non-alcoholic fatty  liver 
disease was performed by comparing liver echogenicity at baseline and at conclusion 
of the study. Liver hyperechogenicity is proportional to the fat content.
xvii
The study initially recruited 87 hypercholesterolemic adults that were randomised in 
two groups of treatment: either placebo (n=44) or tocotrienols 400 mg/day (n=43) for 
one year. Sixty-four subjects concluded the study, 30 in the tocotrienol group  and 34 
in the placebo group. 
The efficacy of the treatment was demonstrated, with subjects treated with 
tocotrienols presenting a significant rate of cure (p=0.014; OR = 3.250; 95% CI = 
1.117-9.456) and amelioration (p=0.021; OR=2.857; 95% CI=1.029-7.934) 
compared to placebo.
The activity of tocotrienols in preventing the onset of non-alcoholic fatty liver 
disease was further evaluated in an animal model. A steatogenic ad hoc diet was 
formulated and administered to mice. Histology  study demonstrated that  animals 
administered with the steatogenic diet developed non-alcoholic fatty liver disease, 
whereas animals with identical diet plus tocotrienols did not develop the disease.
Non-alcoholic fatty liver represents the hepatic component of the metabolic 
syndrome and share the same risk factors with the cerebral component of such 
syndrome: the brain white-matter lesions. Brain white-matter lesions are seen as 
hyperintensities upon magnetic resonance imaging and represent areas of subclinical 
infarcts.
The brains of 172 of the subjects that were screened for presence of non-alcoholic 
fatty liver disease were imaged. Association between brain white-matter lesions and 
ultrasound proven non-alcoholic fatty liver disease was demonstrated for the first 
time in adults above 50 years of age (Chi-square=6.778; p<0.01).
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CHAPTER 1 : INTRODUCTION
1.1 NON-ALCOHOLIC FATTY LIVER DISEASE
Contemporary affluent society is affected by ailments mostly related to its own 
excesses and lifestyle. The World Health Organisation (WHO) reported that about 
1.5 billion adults worldwide, about one in four persons, are overweight including 
about 500 million obese accounting for about 2.6 million obesity-related deaths 
yearly (WHO, 2010a).
Increased intake of processed food, diet high in fats and sugars and reduced physical 
activity have caused the development of a series of health abnormalities that have 
driven medical scientists to name several, apparently  unrelated, diseases as 
components of the metabolic syndrome (Reaven, 1988). The metabolic syndrome is a 
group of potentially deadly, mostly asymptomatic or silent conditions that  comprise 
obesity, hyperglycaemia, arterial hypertension, dyslipidaemia, cardiovascular 
diseases and fatty liver diseases, that are affecting increasing percentages of the 
world population. A recent review regarding the prevalence of metabolic syndrome 
reported a range between 12% and 30% of the world population, with yearly 
increasing incidence (Grundy, 2008), being in agreement with the 2010 WHO data 
on obesity. A 12-year retrospective study on a Canadian population investigating the 
incidence of serious liver events, such as cirrhosis, liver failure and liver 
transplantation, in over 2 million individuals reported a 2-fold increase in risk in 
diabetes compared to matched-control cases, with 8.19 and 4.17 cases per 10,000 
population/year, respectively (Porepa et al, 2010).
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It was not until the ‘80s that fatty  infiltration of the liver, previously considered 
solely  related to excessive alcohol consumption, was distinguished in alcoholic and 
non-alcoholic by Ludwig and colleagues at the Mayo Clinic (Ludwig et al, 1980). 
Until then, non-drinker patients presented with fatty  liver have been considered as 
drinkers in denial. From a pathological point of view, alcoholic and non-alcoholic 
fatty liver are superimposable (James and Day, 1998), thus explaining the earlier 
misconceptions about the disease.
Non-alcoholic fatty  liver disease (NAFLD) is defined as a spectrum of chronic 
hepatic disorders, in absence of significant intake of alcohol, involving fatty 
infiltration of the liver or steatosis of increasing severity varying from macro-
vesicular steatosis to steatohepatitis and initial fibrotic stage (Medina et al, 2004). 
Macro-vesicular steatosis is a condition involving fatty infiltration in more than 5% 
of the liver parenchyma, below this threshold it is considered as minimal findings or 
focal fatty liver (Allard et al, 2008). Non-alcoholic steatohepatitis (NASH) is the 
most severe expression of NAFLD and is characterised by micro- and macro-
vesicular steatosis, inflammation, hepatocytes ballooning and, in certain cases, initial 
stage of fibrosis (Gramlich et al, 2004). Presence of NAFLD is usually hinted by the 
presence of inexplicably and persistently  elevated liver transaminases levels, namely 
alanine transaminase (ALT) and aspartate transaminase (AST), or is an accidental 
finding upon routine ultrasound examinations (Bedogni et al, 2005).
2
1.1.1 Natural History of NAFLD
Until a decade ago, simple steatosis has been regarded as a benign condition, when it 
was shown, in a cohort study that included 772 histological specimens with NAFLD 
diagnosis, that there was higher liver-related deaths in subjects with NASH and 
advanced fibrosis than in those diagnosed with simple steatosis. However, when the 
overall causes of death were evaluated no significant difference was found between 
the two groups. Neoplasm was the most common cause of death, while 
cardiovascular disease-related deaths were equal to that which were liver-related, 
both being in second place (Matteoni et al, 1999). Indeed, these findings discredited 
the perception of steatosis being a harmless condition. Since then, several studies 
considered the progression of NAFLD from steatosis and steatohepatitis up  to 
hepatocellular carcinoma and/or the overall causes of death in these patients. Eksted 
and colleagues (2006), in their 14-year follow up study of 129 subjects, reported a 
significantly increased mortality  in patients diagnosed with NASH compared to 
matched controls. Moreover, 41% of NASH patients progressed to advanced fibrosis; 
development of cirrhosis and hepatocellular carcinoma were also reported. However, 
the most common cause of death in these patients was not liver related, but was once 
again a cardiovascular event (Ekstedt et al, 2006). Such findings indirectly 
corroborated a previously reported 5-year prospective study of cardiovascular events 
investigating the relationship between cardiovascular disease and ultrasound-proven 
NAFLD. It  was shown that NAFLD was positively associated with increased risk of 
cardiovascular events in 248 type II diabetic patients (Targher et al, 2005).
A study on the relationship  between carotid intima-media thickness and NAFLD in 
125 patients, with normal to slightly  elevated liver enzymes and 250 controls 
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demonstrated that NAFLD patients have a significantly higher risk of cardiovascular 
event with an Odds Ratio of 6.9 (Fracanzani et al, 2008). In an unrelated study 
focussed on carotid intima-media thickness as risk factor for cardiovascular events in 
an adult Malaysian population, showed that non-insulin dependent diabetics had 
higher carotid intima-media thickness compared to controls (Yunus et al, 2006). The 
combined findings from Fracanzani (2008) and Yunus (2006) hinted higher risk of 
cardiovascular complications, in particular a cerebrovascular event such as stroke, in 
adults with metabolic syndrome-associated disease as a common risk factor.
Furthermore, NAFLD has been positively associated with insulin resistance and 
hyperinsulinemia in non-diabetic patients with mild hypercholesterolaemia, and 
chronically elevated transaminases, independently of patient’s body weight 
(Marchesini et al, 1999). It  is now accepted that about 12-40% of diagnosed steatosis 
progresses to NASH, with or without initial fibrosis within 8-13 years (de Alwis and 
Day, 2008). Risk of progression from NASH to advanced liver fibrosis was shown to 
be significantly higher in obese patients, even in absence of elevated hepatic 
transaminases values (Garcia-Monzon et al, 2000). Furthermore, in a 10-year 
prospective study on 152 patients with biopsy-proven NASH, it was shown that 
cirrhosis due to NASH can lead to hepatocellular carcinoma in about 14% of the case 
(Sanyal et al, 2006). On the other hand, previous follow-up studies reported a much 
lower occurrence of NASH-related hepatocellular carcinoma. Hui and colleagues 
(2003) surveyed the incidence of hepatocellular carcinoma in patients with hepatitis 
C-associated cirrhosis and NASH-associated cirrhosis. They concluded their 7-year 
follow-up study without reporting any  case of hepatocellular carcinoma amongst the 
23 NASH-associated cirrhotic patients, conversely  the hepatitis C patients presented 
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eight cases of hepatocellular carcinoma. Liver failure, on the other hand, was 
reported as the most common cause of death amongst NASH patients, totalling to 5 
cases out of 23 (22%) patients. Low incidence of hepatocellular carcinoma cases 
were reported in a study of 42 obese NASH patients, with median follow-up of 5-
year, showing progression from NASH to cirrhosis, with only one case of 
hepatocellular carcinoma and one case of cardiovascular event (Powell et al, 1990). 
However, patients sample size could be considered as a severe limitation to the 
studies of Hui and Powell.
A study  on progression and survival rate of NAFLD-related cirrhosis or cryptogenic 
cirrhosis in obese (n=27) and lean patients (n=10) found the obese subject to have 
liver failure in 41% of the patients within two years of disease detection and an 
astonishing 30% of hepatocellular carcinoma within the same follow-up period. Lean 
subjects were also affected, but to a lower extent, by liver failure (20%) and no cases 
of hepatocellular carcinoma were recorded (Ratziu et al, 2002).
A visual summary of the natural history of NAFLD is shown in Fig 1.1.
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Fig. 1.1: Natural history of NAFLD and its pathological progression
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1.1.2 Epidemiology and Susceptibility to NAFLD
NAFLD is considered the most frequently encountered chronic liver disease 
worldwide and the primary cause of elevated liver function test results after hepatitis 
and alcohol (Collier, 2006). Estimates of NAFLD prevalence range from 10% to 
30% of the general adult population (Neuschwander-Tetri, 2001; Cave et al, 2007), a 
tenth of which is expected to meet the diagnostic criteria for NASH (Salt, 2004). 
Majority of the epidemiological studies refer to NAFLD diagnosed by ultrasound 
and/or liver function tests. Ethical and cost considerations prevent large 
epidemiological studies for histology-proven NASH (Targher et al, 2005).
Prevalence estimations are complicated by the severity  range of NAFLD, being 
asymptomatic simple steatosis with normal liver function test largely undetected or 
only diagnosed upon an incidental ultrasonography examination (Bedogni et al, 
2005). The absence of specific biomarkers for NAFLD further complicates 
acquisition of objective prevalence data of the disease. Commonly, cryptogenic 
elevated liver function test results are the first  hint  for the presence of NAFLD, in 
certain cases accompanied by discomfort of the upper-right abdominal quadrant and 
fatigue, independently of severity of the disease (Newton et al, 2008). The 
prevalence of NAFLD increases in selected populations with increased susceptibility 
risks. When populations of patients with concomitant risk factors associated with 
NAFLD, such as obesity, hyperglycaemia, dyslipidaemia are considered, the 
prevalence grows significantly. Data from an Italian sub-cohort study found the 
presence of NAFLD in 257 normal-weight adults to be about 16%, while in obese 
adults grew to nearly 76%, a 4.6-fold increased risk (Bellentani et al, 2000). This 
value is in agreement with smaller reported studies in obese subjects. Matteoni and 
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colleagues (1999) diagnosed NAFLD in 70% of 132 obese patients. Similarly, 
Angulo and co-investigators (1999) reported presence of NAFLD in 60% of 144 
obese adults.
Diabetes, hyperglycaemia and insulin resistance are strongly associated with NAFLD 
and this is reflected in a prevalence of the disease of nearly 70% in diabetics (Tolman 
et al, 2007). Even though obese diabetics show higher prevalence rate of NAFLD, 
non-obese diabetics are not immune to the disease. Moreover, significant differences 
in prevalence of ultrasound-proven NAFLD in type I and type II diabetes exist. A 
study found that type I diabetics had a NAFLD prevalence of 24%, whereas in type 
II diabetics, the prevalence was increased to 80% (Gaiani et al, 2009).
A study on 105 severely  obese patients found that prevalence of NASH increased 
with the type and number of concomitant metabolic abnormalities. In patients 
without diabetes and arterial hypertension, less than 10% was diagnosed with NASH, 
in patients with arterial hypertension, NASH was found to be increased to 30%, in 
diabetics 60% and in diabetics with arterial hypertension to be above 80%. Thus, 
predictive factors for NASH in severely  obese adults were found to be arterial 
hypertension, insulin resistance and diabetes, besides ALT levels. Interestingly, 
alcohol consumption was not associated with NASH. Indeed, a moderate 
consumption of alcohol, up  to two standard drinks per day, was described as 
protective against NAFLD (Dixon et al, 2001).
Exclusion of concomitant liver-related diseases, particularly viral hepatitis, is helpful 
for the diagnosis of NAFLD. However, the severity  of NAFLD should be assessed at 
first with ultrasound examinations and subsequently, if appropriate, with a liver 
biopsy. Magnetic resonance imaging (MRI) and computed tomography (CT) scan are 
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capable of diagnosing NAFLD, however cost and/or length of the examination, 
together with comparable levels of specificity and sensitivity  with ultrasound 
examinations do not favour MRI and CT diagnostic techniques over ultrasonography 
(Mehta et al, 2008).
1.1.3 Pathogenesis of NAFLD
Little is known about the aetiology of NAFLD, even though several mechanisms 
have been postulated for the progression from simple steatosis to NASH. Letteron 
and colleagues (1996) showed that administration of ethanol, tetracycline, 
chlortetracycline, demeclocycline, amineptine, amiodarone, pirprofen or valproate 
(all of them recognised as steatogenic compounds) caused microvescicular hepatic 
steatosis. Increased hepatic synthesis and release of free-fatty acids led to steatosis 
via lipid peroxidation. This pathway that led to microvesicular deposition of fat, in 
form of triglycerides (TG) in the liver, was found to be independent of the 
steatogenic compound used. It was hypothesised that  the mere presence of intra-
hepatic fat might be the initial step for the development of steatohepatitis (Letteron et 
al, 1996).
A study on alcoholic liver disease (ALD) proved that animals fed with ethanol 
developed liver injury, but when lipid peroxidation was prevented with the 
administration of gadolinium trichloride (GdCl3), there was a reduction of 
inflammation and necrosis (Arteel, 2003), being accord to Letteron’s study that lipid 
peroxidation was involved. GdCl3 has been proven to reduce hepatic fibrosis induced 
by carbon tetrachloride (CCl4) in rats through depletion of Kupffer cells (a type of 
cells present in the liver). Administration of CCl4 caused oxidative stress, that 
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induced an increased response by Kupffer cells with consequent release of cytokines 
(Rivera et al, 2001). Similar mechanism to CCl4 has been known for ethanol abuse 
(Hoek and Pastorino, 2002).
Similarities in the pathogenesis of alcoholic and non-alcoholic liver injuries were 
studied in mice fed control diet plus ethanol, methionine-choline deficient diet, 
ethanol plus methionine-choline deficient diet or control diet (Gyamfi et al, 2008). It 
was shown that ethanol, methionine-choline deficient diet and the combination of 
ethanol and methionine-choline deficient diet caused oxidative stress, with 
production of reactive oxygen species that led to the inhibition of the peroxisome 
proliferator-activated receptor-alpha (PPAR-α). Ethanol causes lipid peroxidation of 
membrane phospholipids and damages the methionine-adenosyl transferase, 
followed by depletion of methionine (Colell et al, 1998).
Oxidative stress, induced by ethanol ingestion or diet  high in unsaturated fatty acids 
(in the ALD or NAFLD models respectively) was known to cause liver damage 
through the release of pro-inflammatory adipocytokines, in particular the tumour 
necrosis factor-alpha (TNF-α) (Nanji et al, 1995). Inhibition of PPAR-α, associated 
with ethanol consumption or obesity  in humans, caused lipogenesis and intra-hepatic 
fat deposition. This represents the pathway of the first  hits involved in development 
of steatosis and its subsequent progression to alcoholic- or non-alcoholic-
steatohepatitits (Gyamfi et al, 2008). Adipose tissue is known to release several 
products active in carbohydrate and lipid metabolism. In the case of carbohydrate 
metabolism, the products are leptin and adiponectin, whereas in lipid metabolism, the 
products are apolipoproteins and pro-inflammatory adipocytokynes such as TNF-α 
and the pro-fibrogenic interleukyn-6 (IL-6) (Brunt, 2004). Increased release of TNF-
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α and reduced release of adiponectin in presence of obesity, interferes with the 
reactivity of insulin-receptors leading to insulin resistance and promotes the release 
of long-chain fatty acids (Day, 2002). This might explain the strong association of 
NAFLD with insulin resistance (Marchesini et al, 1999; Tolman et al, 2007), with 
obesity  (Matteoni et al, 1999; Angulo et al, 1999; Bellentani et al, 2000) and with the 
combination of both, insulin resistance/diabetes and obesity  (Tolman et al, 2007; 
Gaiani et al, 2009). Moreover, hepatocyte injury induced by TNF-α-mediated 
production of reactive oxygen species has been found to be exacerbated by ethanol 
administration (Colell et al, 1998).
Low levels of insulin delay glucose uptake by adipocytes and inhibit lipolysis in 
combination with increased release of TNF-α, particularly in overweight or obese 
individuals, leads to augmented long-chain fatty acids production and consequent 
increased TG synthesis and deposition in the hepatocytes (Bradbury and Berk, 2004). 
Thus, insulin resistance and obesity might be considered amongst the first causal 
insults for the development of steatosis with inflammation caused by increased 
oxidative stress and lipid peroxidation representing the second hits for the 
progression from steatosis to NASH (Day, 2006), as shown in Fig. 1.2.
Dietary factors and sedentary lifestyle play a pivotal role in the development of 
NAFLD. Increased intake of food rich in fats and carbohydrates and reduced 
physical activity lead to development of obesity, thus initiating the vicious cycle that 
contributes to NAFLD, diabetes and cardiovascular disease.
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Fig. 1.2: The “Two Hits” theory for onset of steatosis and its progression to NASH
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1.1.4 Management and Proposed Treatments of NAFLD
In the quest for the discovery  of a suitable treatment for NAFLD, several approaches 
have been investigated in clinical trials, such as lifestyle modifications, alone or in 
combination with pharmacological treatments with a number of agents belonging to 
several therapeutical classes.
Common working hypothesis to all investigations was an intervention on the 
metabolic conditions that were commonly associated with NAFLD.
Lifestyle Modifications
Hitherto there is no pharmacological treatment for NAFLD and the only 
recommendations are lifestyle modifications, such as weight loss, diet and physical 
exercise (American Gastroenterological Association, 2002). Since NAFLD is closely 
related to obesity, the first logical approach is to tackle the excess of body fat.
A 3-month study in obese Japanese patients had shown that a restricted diet (25 kCal/
kg of ideal body weight) plus physical exercise were helpful in improving liver 
enzyme levels and histological findings of steatosis, but not inflammation and 
fibrosis (Ueno et al, 1997). Kugelmas and colleagues (2003) compared the effects of 
diet and exercise (30 min of daily jog) with or without the administration of 800 mg/
day of vitamin E, in two groups of 16 patients each with biopsy-proven NASH. At 
conclusion of a 12-week period, they found that vitamin E did not to influence the 
outcomes of the study. Thus, for statistical purposes, they pooled the two groups 
together and concluded that a weight reduction of about 5% was the single 
independent predictive factor to induce significant improvements in liver 
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transaminases (Kugelmas et al, 2003). However, histopathological data on repeated 
liver biopsy were not disclosed.
Petersen and colleagues (2005) proved the benefit of a moderate weight loss (8 kg or 
10% reduction in body weight), achieved solely through diet, in sedentary  type II 
diabetic patients with MRI-proven steatosis and normal liver enzymes. All the 
subjects were found with significant reduction of hepatic fat content at conclusion of 
the study (Petersen et al, 2005).
Orlistat, a drug that prevents fat absorption through inhibiting gastric and pancreatic 
lipases (Lucas et al, 2003), was recently investigated in patients with NASH. An 
interventional 24-month study on the effects of orlistat, besides diet, in overweight 
subjects with biopsy-proven NASH was conducted by Harrison and colleagues 
(2009). Overall, no advantage was seen in the orlistat  group compared to the control 
group, that was under dietary regimen alone, with regard to body weight reduction 
and histopathological score for NASH. However, Harrison (2009) reported a 
significant improvement of steatosis in all subjects that lost 10% or more of their 
body weight, thus confirming earlier findings from Petersen (2005). Hatzitolios and 
colleagues (2004) reported improvement of liver transaminases levels and liver 
echogenicity in 3 groups of dyslipidemic patients treated with omega-3, atorvastatin 
or orlistat. However, the improvements were found to be related to weight loss and 
not to any of the treatments assigned (Hatzitolios et al, 2004).
Lipid Lowering Drugs
The high prevalence of NAFLD in dyslipidaemic patients encouraged researchers to 
investigate the effects of lipid lowering drugs, such as statins, in NAFLD. Statins are 
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inhibitors of hepatic 3-hydroxy-3-methylglutaril-coenzyme A (HMG-CoA) 
reductase, an enzyme converting HMG-CoA into the cholesterol-precursor 
mevalonic acid (Stancu and Sima, 2001).
Atorvastatin, the most widely  prescribed cholesterol lowering drug, was recently 
investigated in 31 dyslipidaemic patients with biopsy-proven NASH (Hyogo et al, 
2008). After 24 months of treatment with atorvastatin, all subjects showed significant 
reduction in liver enzymes and, not surprisingly, in lipid profile. Biopsy  which was 
repeated in 17 out of the 31 patients, showed significant histological changes 
recorded for steatosis, but not for other NASH parameters, such as ballooning, 
inflammation and fibrosis. However, 4 out of 17 patients, showed pathology 
progression. On all 31 patients, CT scan was performed to determine liver density, 
that is inversely correlated to fat content, and confirmed a decreased presence of fat 
infiltration, although it was not statistically significant (Hyogo et al, 2008). As 
mentioned earlier, study by Hatzitolios (2004), showed that intervention with 
atorvastatin was found ineffective in NAFLD.
Another lipid lowering agent, the fibrate gemfibrozil, an activator of PPAR-α, was 
investigated in a brief prospective study of NASH patients with elevated liver 
transaminases. After 4 weeks of treatment the 23 patients in the drug group  were 
found to have significantly reduced ALT, AST and gamma-glutamyl transpeptidase 
(GGT) levels, even though the values were still above their respective upper limit. 
Whereas, amongst the 23 untreated control patients, no changes were seen 
(Basaranoglu et al, 1999). Liver biopsy was not repeated on these subjects. Thus, it 
was not possible to evaluate if liver enzymes changes were reflective of actual 
histological changes.
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Insulin Sensitising Drugs
Due to the proven association diabetes-NAFLD and the role played by insulin 
resistance in the progression of NAFLD (Day, 2002), insulin sensitising drugs have 
been investigated for the treatment of NAFLD.
The effects of metformin, a biguanide oral antidiabetic drug that  suppresses hepatic 
gluconeogenesis (Kirpichnikov et al, 2002) has been investigated in several, mostly 
open label, trials. The rationale for metformin clinical trials was based on an animal 
study that reported the efficacy of this drug in reversing fatty liver in genetically 
engineered obese mice (Lin et al, 2000). Shortly after Lin’s publication, the first 
human trial on metformin (as proposed treatment for NASH) versus diet alone in 
non-diabetic, non-obese subjects was described by Marchesini and colleagues 
(2001a). A significant reduction of liver volume, assessed using ultrasound, was 
reported in the metformin group  and, to a lower extent, in the control group. ALT 
levels were reported to be significantly lower at the end of the 4-month study in the 
metformin group compared to baseline (Marchesini et al, 2001a).
Metformin was also investigated in 15 adults patients, including a single diabetic, 
with slightly elevated (up to 1.5 times the normal values) liver aminotransferases and 
biopsy-proven NAFLD (Nair et al, 2004). Improvement in liver enzymes levels was 
seen only  at the 3-month follow-up, but was not sustained thereafter. At conclusion 
of 1-year treatment, the results were far from encouraging, an improvement in 
steatosis and NASH-related inflammation was recorded in only 30% and 20% of 
patients, respectively (Nair et al, 2004).
Contrasting results were obtained by Schwimmer and colleagues (2005), who 
evaluated metformin administration in 10 obese, non-diabetic paediatric patients in 
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an open-label study. At baseline all patients had histology-proven NASH with 
elevated liver transaminases. The liver fat content was measured by MRI, thus no 
data on inflammation was obtained. At completion of the 24-week investigation, 
liver enzymes were found to be significantly lower. ALT and AST returned within the 
normal limits in 40% and 50% of the patients, respectively. Furthermore, hepatic fat 
significantly decreased in 90% of the children (Schwimmer et al, 2005). However 
liver biopsies were not repeated, thus no data on histology changes were available.
In another open label study, with a follow-up  of 12 months, metformin, diet or 
vitamin E were compared in three groups of non-diabetic patients with biopsy-
proven NAFLD. Improvement of liver aminotransferases was reported in all patients 
and it was associated with weight loss, independently of treatment, even though a 
moderate advantage for metformin was observed (Bugianesi et al, 2005). A longer 
study, with a follow-up of 24 months, on 57 overweight  or obese children and 30 
controls confirmed that metformin was not superior to lifestyle modifications in 
improving neither liver enzymes levels nor NAFLD (Nobili et al, 2008a). The latest 
study on metformin was conducted in 26 overweight or obese patients with biopsy-
proven NASH and non-clinically  significant elevation of liver enzymes. After 48 
weeks, a significant improvement in histology findings was detected in about half of 
the patients. However, in the responders group there was a strong association 
between improvement and weight loss (Loomba et al, 2009).
In summary, no concrete evidence supported the use of metformin, at  dose of 1-2 g/
day, in the treatment of NAFLD. However, another class of insulin sensitising agents 
attracted the attention of many researchers, namely  the thiazolidinediones. The 
thiazolidinediones class of antidiabetics, reduces insulin resistance in the liver and 
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other tissues through stimulating the peroxisome proliferator-activated receptor 
gamma (PPAR-γ) and alpha (PPAR-α) (Smith, 2001).
Rosiglitazone, a drug belonging to the thiazolidinediones class, was investigated in a 
48-week open-label study of 30 adults with elevated ALT and biopsy-proven NASH. 
After treatment, significant reduction was found in ALT, GGT, alkaline phosphatase 
(ALP) and insulin sensitivity levels. Positive results were also found for steatosis, but 
not for NASH in the 22 patients that underwent repeated liver biopsy. No correlation 
was found between ALT and histology  changes. However, body weight was found to 
have increased significantly. Serious adverse reactions led to withdrawal of 10% of 
participants to the study (Neuschwander-Tetri et al, 2003).
A long-term assessment of rosiglitazone in 63 patients with histology-proven NASH 
showed a significant reduction for transaminases levels and steatosis, but not for 
fibrosis and inflammation compared to placebo during the first year of the double-
blinded study (Ratziu et al, 2008). Subsequently, 40 of these subjects continued the 
study, that became a longitudinal open label trial with all patients given rosiglitazone, 
for a further 24-month period (Ratziu et al, 2009). The results indicated no further 
benefit from a prolonged therapy with rosiglitazone as compared to 1-year treatment. 
Results obtained with the patients previously on placebo during the 2 years of 
treatment with the drug, were similar to those obtained during the first year of the 
study by the original rosiglitazone group  (Ratziu et al, 2009). No activity on 
inflammation and/or fibrosis was seen even in the longitudinal study. Thus, the 
results of the study  discredited the hypothesis that long-term administration would 
have been needed to improve inflammation and/or fibrosis. A median gain weight of 
2 kg was reported, with 36% of the patients gaining more than 3 kg. Furthermore, 
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adverse events occurred among the patients far too frequently to consider 
rosiglitazone as a well tolerated drug. Adverse events reported were asthenia (36%), 
muscular cramps (26%), swollen legs (25%), gastrointestinal symptoms (19%), 
headache (11%) and dyspnea (4%).
Another thiazolidinediones drug, pioglitazone, was investigated in a 16-week open-
label clinical trial in 14 type 2 diabetic patients with normal liver function test. This 
study, focussed mostly on the hepatic glucose metabolism, showed pioglitazone to be 
beneficial in significantly reducing insulin resistance, fasting plasma glucose and 
hepatic fat content, determined by MRI. Liver AST and ALT values, even though 
normal at baseline, were significantly reduced at conclusion of the study. However, 
body weight significantly increased (Bajaj et al, 2003). These positive results on risk 
factors associated with NAFLD prompted the initiation of several pilot studies. One 
investigation enrolled 18 non-diabetic, overweight or obese patients with elevated 
liver enzymes and biopsy-proven NASH. At the end of the 48 weeks of treatment 
with pioglitazone, the liver function test values were significantly reduced, with 
normalisation in about 70% of the patients, as well as liver fat content, as measured 
by MRI. Moreover, repeated biopsy confirmed an overall amelioration of histological 
parameters, such as steatosis, NASH, inflammation and fibrosis (Promrat et al, 
2004). Also in this study body weight increased significantly.
The hypothesis that not only insulin resistance is involved in NASH, but also 
oxidative stress is amongst the contributing elements for the onset of NASH, led to 
initiation of a pilot trial with a combination therapy of antioxidant and oral 
antidiabetic drug (Sanyal et al, 2004). Twenty non-diabetic patients with histology-
proven NASH, were randomised into two arms and administered either vitamin E (as 
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alpha-tocopherol) alone or pioglitazone plus vitamin E. At conclusion of the 6 
months study amelioration in steatosis was recorded for both arms, with a greater 
advantage for the combination therapy  (Sanyal et al, 2004). This pilot  study was 
scaled-up to include almost 250 patients and the study design was fine-tuned to 
identify which agent of the combination therapy had greater influence on the 
response. Moreover, a placebo group was included besides the vitamin E and the 
pioglitazone arms (Sanyal et al, 2010). The follow-up period was lengthened to 96 
weeks and the dose of alpha-tocopherol administered doubled to 800 mg/day. After 2 
years of treatment, patients were found with improved steatosis in 31%, 54% and 
69% of cases for placebo, vitamin E and pioglitazone, respectively. Hepatic ALT and 
AST decreased in a comparable manner for vitamin E and pioglitazone, however 
they  rebounded towards baseline levels once the treatments were discontinued. The 
pioglitazone group gained an average of 5 kg during the study, compared to vitamin 
E and placebo groups where body weight was maintained at baseline levels (Sanyal 
et al, 2010). The results obtained were essentially negative for pioglitazone treatment 
which did not lead to any significant level of histological improvement in NASH 
(primary outcomes), even though an amelioration in the overall NAFLD score 
(secondary  outcomes) was found. However, vitamin E treatment led to significant 
improvement for both, primary and secondary  outcomes in this cohort of non-
diabetic patients (Sanyal et al, 2010).
Hepatoprotective Agents and Antioxidants
Several hepatoprotective agents, either drugs or supplements, have been investigated 
for the treatment of NAFLD. Vajro and colleagues (2000) studied ursodeoxycholic 
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acid, a secondary bile acid used for removal of cholesterol gallstones, in 31 obese 
children with liver abnormalities diagnosed either by blood chemistry or by 
ultrasound examination. This open-label study, comparing the effects of 
ursodeoxycholic acid with or without diet  on ALT or ultrasound abnormalities, 
showed that diet associated with weight loss to be more affective than 
ursodeoxycholic acid in improving liver abnormalities (Vajro et al, 2000).
In another double-blind placebo-controlled, ursodeoxycholic acid was evaluated in 
166 patients with biopsy-proven NASH. After two years of intervention, no 
significant change was associated with the use of ursodeoxycholic acid compared to 
placebo (Lindor et al, 2004).
Mice fed choline-deficient diet have been reported to develop hepatitis similar to 
human hepatitis (Grattagliano et al, 2000). Phosphatidylcholine, a choline-
conjugated phospholipid and essential membrane component, is commonly 
employed for improving general liver health and as such was investigated in type 2 
diabetic patients with ultrasound-proven NAFLD. In an open-label study conducted 
by Poongothai and colleagues (2005), phosphatidylcholine appeared to be beneficial 
in reducing the liver function markers and ameliorating the hepatic echotexture. 
Liver function markers such as ALT and AST showed a significant reduction within 
two months of treatment, meanwhile GGT showed a significant reduction after six 
months of treatment. Moreover, it was reported that the amelioration of the NAFLD 
score was directly  related to the baseline severity, thus patients with more severe 
initial score were more likely to see a greater improvement compared to their milder 
counterparts (Poongothai et al, 2005). The suggested mechanisms of action for 
phosphatidylcholine was its cholesterol lowering activity. However, the authors 
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could not  exclude that  an improved glycaemic control in these patient played a role 
in improving the overall study outcomes.
Another approach to NAFLD treatment was based on the use of antioxidants, due to 
hepatic lipid peroxidation (Letteron et al, 1996) and increased oxidative stress levels 
observed in subjects with NAFLD (Haque and Sanyal, 2002). Vitamin E, one of the 
most potent antioxidant, has been tested in a number of clinical trials over the last 
decade.
Lavine (2000) treated 11 obese paediatric patients, with elevated liver transaminases 
and ultrasound-proven NAFLD, with synthetic alpha-tocopherol. The dose employed 
ranged from 400 mg to 1200 mg a day. The study  lasted between 4 and 10 months, at 
conclusion of which reduction of ALT and AST values was found to be significant. 
compared to baseline. However, ultrasound examination was not repeated (Lavine, 
2000).
Efficacy of alpha-tocopherol was investigated in a study  that included 12 adults with 
NASH and 10 adults with steatosis (Hasegawa et al, 2001). All patients were given a 
6-month entry dietary  therapy and were later treated with 300 mg/day of alpha-
tocopherol for another 6-month period. Common to all patients were impaired 
glucose tolerance, hyperlipidemia and elevated liver markers. At conclusion of the 
study, it was found that the 6 months diet therapy has no effect on the liver enzymes 
in the NASH patients, but a normalisation of the values was recorded only  after 
alpha-tocopherol treatment was initiated. On the other hand, patients with steatosis 
benefited from the diet more than from alpha-tocopherol treatment. In this group of 
patients, a normalisation of the liver enzymes was noted after dietary therapy and 
remained stable after the alpha-tocopherol treatment. Biopsy  performed in 9 out of 
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12 patients in the NASH group showed amelioration of steatosis, inflammation and 
fibrosis (Hasegawa et al, 2001).
A paediatric, single-blind placebo-controlled investigation involving 28 obese 
children with similar inclusion criteria of that of Lavine (2000) was also carried out 
using vitamin E (alpha-tocopherol). Vitamin E was given at a dose of 400 mg/day  for 
the initial 2 months and subsequently reduced to 100 mg/day  for 3 months. 
Controlled diet was given to both, the vitamin E and placebo groups. The two groups 
showed similar results in terms of ALT reduction as well as ultrasound examination 
(Vajro et al, 2004). No clinical improvement was attributed to alpha-tocopherol.
Harrison and co-investigators (2003) conducted a prospective, randomised trial on 45 
subjects with NASH assigned to receive vitamin E and vitamin C or placebo for 6 
months. The dose of both vitamins given was 1000 mg daily. When liver biopsy  was 
repeated, the treatment with vitamins was found to have improved the diagnosis of 
NASH compared to baseline, but the changes were not significant as compared to 
placebo. Moreover, there was no improvement in ALT levels and/or inflammation 
(Harrison et al, 2003).
As previously discussed, the open-label study of Kugelmas (2003), showed that 
vitamin E plus lifestyle modification did not produce any  significant outcomes as 
compared to lifestyle modification alone in NAFLD. Also, the study by Sanyal  et al 
(2004) about a combination therapy of pioglitazone and alpha-tocopherol versus 
alpha-tocopherol alone, that showed amelioration of NASH in both arms, have been 
previously discussed.
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A study that enrolled 90 NAFLD paediatric patients investigating combined 
antioxidant treatment with alpha-tocopherol (600 IU/day) plus ascorbic acid (500 
mg/day) or placebo was reported by Nobili et al (2008b). Obese children were 
prescribed tailored hypocaloric diets, whereas isocaloric personalised diets were 
prescribed to children with normal weight. All patients were advised to increase 
physical activity. Even though only 53 out of 90 children completed the 2-year study, 
it was claimed sufficient for concluding that lifestyle modifications were associated 
with an overall improvement in the NAFLD score and that the antioxidant therapy 
did not provide any significant advantage (Nobili et al, 2008b).
Despite the contradicting therapeutic results obtained with alpha-tocopherol so far 
and in light of the previously discussed 3-way study by  Sanyal’s group  (2010) on 
pioglitazone, vitamin E or placebo in NASH patients, treatment of NAFLD with 
vitamin E is hitherto considered the most promising.
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1.2 BRAIN WHITE-MATTER LESIONS
Brain white-matter abnormalities were first  and briefly  described at the end of 
nineteenth century by Binswanger in the contest of a clinical case of progressive 
decline of brain functionalities. Soon after, Alzheimer, in his description of similar 
cases, attributed these white-matter changes to arteriosclerosis of the brain vessels 
(Pantoni and Garcia, 1995). Until the introduction of CT scan and MRI, white-matter 
changes could only  be ascertained during autopsy. These recent imaging techniques 
provided the opportunity  to detect white-matter changes or white-matter lesions 
(WML) without having to wait for autopsy. Thus, it  became evident that not only 
patients afflicted by Alzheimer’s disease had WML, but also other pathologies could 
be associated with WML. A correlation study between histopathological changes and 
the hyperintensity  signals obtained from MRI scans of deceased elderly, confirmed 
the presence of actual abnormalities in the brain white-matter (Grafton et al, 1991). 
However, no indication on the pathogenesis of WML was obtained.
Being an asymptomatic condition and to avoid the designation of a new pathology 
for patients, the term leuko-araiosis was coined (Hachinski et al, 1987). Leuko-
araiosis derives from the Greek words leuko (white) and araiosis (rarefaction). 
Immunohistochemical investigation in three groups of patients with cardiovascular 
disease, Alzheimer’s disease and control, concluded that the blood-brain barrier is 
altered to higher extent in subjects with cardiovascular disease than Alzheimer’s 
disease, suggesting this alteration might be involved in the development of WML. 
Moreover, it  was noted that  Alzheimer’s disease subjects had lesser changes, both in 
number and severity, than cardiovascular disease subjects, indicating the possibility 
of separate pathological pathways (Tomimoto et al, 1996).
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